Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2025 Showcase Research from Its Investigational Treatments for Lysosomal Storage Disorders
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposium™ 2025
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting Growth Hormone Therapy
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for Mucopolysaccharidosis Type IIIB in Japan
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Announces Completion of Clinical Trial Notification Process in Japan for Phase I Study of JR-441 for Mucopolysaccharidosis Type IIIA
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal Disorders
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
MEDIPAL and JCR Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease Community
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
Angelini Pharma and JCR Pharmaceuticals Announce Global Collaboration for the Development and Commercialization of Novel Biologic Therapies in Epilepsy
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative Disease
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals to Present at the 18th Annual WORLDSymposiumTM 2022
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
JCR Pharmaceuticals Receives the WORLDSymposium™ New Treatment Award for IZCARGO® (Pabinafusp Alfa)
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.